EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes

A Emile J Hendriks iD, M Loredana Marcovecchio, Rachel E J Besser, Ezio Bonifacio, Kristina Casteels, Helena Elding Larsson, Gita Gemulla, Markus Lundgren, Olga Kordonouri, Roberto Mallone, Flemming Pociot, Agnieszka Szypowska and 6 more

Diabetes/Metabolism Research and Reviews · 2024-02 · 40 (2)

DOI: 10.1002/dmrr.3777 ↗

At a glance

Journal article in Diabetes/Metabolism Research and Reviews, published online on 2024-02-20. Written by A Emile J Hendriks and 17 co-authors. Institution: Department of Paediatrics, University of Cambridge, Cambridge, UK. Major MEDLINE topics: Diabetes Mellitus, Type 1, Diabetic Ketoacidosis. Cited 43 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background/Aim Type 1 diabetes is an autoimmune disease that involves the development of autoantibodies against pancreatic islet beta‐cell antigens, preceding clinical diagnosis by a period of preclinical disease activity. As screening activity to identify autoantibody‐positive individuals increases, a rise in presymptomatic type 1 diabetes individuals seeking medical attention is expected. Current guidance on how to monitor these individuals in a safe but minimally invasive way is limited. This article aims to provide clinical guidance for monitoring individuals with presymptomatic type 1 diabetes to reduce the risk of diabetic ketoacidosis (DKA) at diagnosis.

Methods

Expert consensus was obtained from members of the Fr1da, GPPAD, and INNODIA consortia, three European diabetes research groups. The guidance covers both specialist and primary care follow‐up strategies.

Results

The guidance outlines recommended monitoring approaches based on age, disease stage and clinical setting. Individuals with presymptomatic type 1 diabetes are best followed up in specialist care. For stage 1, biannual assessments of random plasma glucose and HbA1c are suggested for children, while annual assessments are recommended for adolescents and adults. For stage 2, 3‐monthly clinic visits with additional home monitoring are advised. The value of repeat OGTT in stage 1 and the use of continuous glucose monitoring in stage 2 are discussed. Primary care is encouraged to monitor individuals who decline specialist care, following the guidance presented.

Conclusions

As type 1 diabetes screening programs become more prevalent, effective monitoring strategies are essential to mitigate the risk of complications such as DKA. This guidance serves as a valuable resource for clinicians, providing practical recommendations tailored to an individual's age and disease stage, both within specialist and primary care settings.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 1Diabetic KetoacidosisChildAdolescentAdultHumansAutoantibodiesBlood Glucose Self-MonitoringBlood Glucose

Author keywords

monitoringpresymptomatic type 1 diabetesprimary carescreeningspecialist carestaging

Substances

AutoantibodiesBlood Glucose

Authors and institutions

  • Department of Paediatrics, University of Cambridge, Cambridge, UK.
  • Department of Paediatric Diabetes and Endocrinology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Department of Paediatrics, University of Oxford, Oxford, UK.
  • Technische Universität Dresden, Center for Regenerative Therapies Dresden, Dresden, Germany.
  • German Center for Diabetes Research (DZD e.V.), Munich, Germany.

ORCID profiles: A Emile J Hendriks

Cite

APA

Hendriks, A. E. J., Marcovecchio, M. L., Besser, R. E. J., Bonifacio, E., Casteels, K., Elding Larsson, H., Gemulla, G., Lundgren, M., Kordonouri, O., Mallone, R., Pociot, F., Szypowska, A., Toppari, J., Berge, T. V. D., Ziegler, A. G., Mathieu, C., Achenbach, P., & INNODIA consortium, the Fr1da Study Group and the GPPAD Study Group (2024). Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes. Diabetes/Metabolism Research and Reviews, 40(2). https://doi.org/10.1002/dmrr.3777

Vancouver

Hendriks AEJ, Marcovecchio ML, Besser REJ, Bonifacio E, Casteels K, Elding Larsson H, et al. Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes. Diabetes/Metabolism Research and Reviews. 2024;40(2). doi:10.1002/dmrr.3777

BibTeX
@article{Hendriks2024,
  author = {Hendriks, A Emile J and Marcovecchio, M Loredana and Besser, Rachel E J and Bonifacio, Ezio and Casteels, Kristina and Elding Larsson, Helena and Gemulla, Gita and Lundgren, Markus and Kordonouri, Olga and Mallone, Roberto and Pociot, Flemming and Szypowska, Agnieszka and Toppari, Jorma and Berge, Thekla von dem and Ziegler, Anette G and Mathieu, Chantal and Achenbach, Peter and INNODIA consortium, the Fr1da Study Group and the GPPAD Study Group, INNODIA consortium, the Fr1da Study Group and the GPPAD Study Group},
  title = {Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2024},
  volume = {40},
  number = {2},
  doi = {10.1002/dmrr.3777}
}
Start for free →